Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07651852
Recruiting Observational

Globe Registry: Globe® Pulsed Field System Registry Study for Treating Patients With Symptomatic Atrial Fibrillation

NCT07651852 · tracked via the Priya Life Science USA tracker
Sponsor
Kardium Inc
Phase
Observational
Started
2026-10-09
Last updated
2026-10-26

Condition(s) studied

Atrial Fibrillation

Investigational drug(s) / intervention(s)

Globe Pulsed Field System

Globe Pulsed Field System: Ablation and atrial mapping with the Globe Pulsed Field System

Study summary

This post-market registry is designed to collect real world data on the use of the Globe PF System for the treatment of atrial fibrillation (AF).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria: * Patients with a planned ablation procedure using the commercially available Globe PF System Key Exclusion Criteria: * Patients whose life expectancy is 1 year or less * Contraindication to left atrial catheter ablation or PF ablation * Current enrollment in any investigational study of a medical device, biologic, or drug not pre-approved by Kardium

Primary outcome measure(s)

  • Effectiveness endpoint — 12 months
    Rate of 12-month treatment success following ablation using the Globe PF System.
  • Safety endpoint — 7 days
    Rate of subjects with one or more major adverse events up to 7 days following the index ablation procedure.

Trial sites (2)

FacilityCityRegionStatus
Arrhythmia Research Group Jonesboro Arkansas Recruiting
Overlake Hospital Bellevue Washington Recruiting

More Kardium Inc. trials in the USA

Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation Active, not recruiting

Other trials for the same condition

Tracking Results of Ablations to Combat AF Registry Generation 2 Recruiting
A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation Recruiting
A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF) Active, not recruiting
HeartBeam ECG Registry Recruiting
A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07651852 on ClinicalTrials.gov ↗ ← All trials in the USA